BioCorRx Inc.

AI-generated fair value estimate for this company.

Method: 10-year revenue-growth DCF: $0.651M TTM revenue base from LUCEMYRA distribution, the company's first meaningful revenue; growth 80%/60%/45%/35%/25% years 1-5, then 15%/10%/8%/6%/5% years 6-10; FCF margin improving from -200% in year 1 through breakeven around years 4-5 to 17% by year 10 as fixed corporate overhead spreads over growing distribution revenue; 25% discount rate (going-concern doubt disclosed in its 10-Q, heavy debt load); 3% terminal growth; approximately -$2M estimated net debt; ~29.76M shares outstanding.

Reasoning: BioCorRx only just began generating meaningful revenue after years of near-zero sales and has an explicit going-concern warning and heavy debt, so a DCF anchored to this early, fast-growing but thin revenue base, discounted at a distress-level rate, is more defensible than valuing off currently very negative earnings.